Research programme: cyclin-dependent kinase inhibitors - GPC Biotech

Drug Profile

Research programme: cyclin-dependent kinase inhibitors - GPC Biotech

Alternative Names: GPC 285978; GPC 286199; RGB-286199; RGB-344064

Latest Information Update: 13 Jul 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GPC Biotech AG
  • Developer Agennix AG
  • Class Pyrazoles; Small molecules
  • Mechanism of Action Cyclin-dependent kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 30 Aug 2007 GPC Biotech slows down certain ongoing activities and no further commitments to be made to its cell-cyle inhibitor programme; development is suspended until further resources are available
  • 02 May 2006 Preclinical trials in Cancer in USA (unspecified route)
  • 21 Jun 2005 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top